About This Fund
Alta Life Sciences, the Barcelona-based venture capital firm specialising in life sciences and healthcare innovation, launched Alta Life Sciences Spain I FCR with a first closing in September 2016 and completed the final close in December 2019, raising EUR 79 million in total investor commitments. The fund is registered with the CNMV (Comisión Nacional del Mercado de Valores) as a Fondo de Capital Riesgo (registration number 203), the standard closed-end private capital structure under Spanish law. The ISIN of the fund is ES0108631005. Alta Life Sciences Spain I FCR targets Spanish and Southern European biotechnology, biopharmaceutical, medical devices and diagnostics, genomics, and digital health companies across the full development spectrum from seed through Series C and beyond, with a co-investment model that places fund managers alongside company leadership teams.
The fund's investment strategy reflects Alta Life Sciences' conviction that the Spanish life sciences ecosystem — particularly the research-commercialisation bridge in Barcelona and Madrid — is significantly underserved relative to its scientific output. Portfolio companies receive not only capital but also strategic support for international expansion, partnership development, and clinical or regulatory navigation. Alta Life Sciences Spain I FCR has backed several life sciences companies that have gone on to raise significant follow-on rounds from international investors, illustrating the fund's role as a credibility anchor for early-stage Spanish biotech.
Following a strategic integration announced in October 2025, the fund portfolio is now co-managed by AltamarCAM Partners and Asabys Partners, following the incorporation of the Alta Life Sciences investment team under the Aliath Bioventures banner into Asabys. The combined platform manages over EUR 400 million in life sciences-focused assets, positioning it as one of the largest healthcare venture capital managers in Southern Europe. Portfolio companies of Alta Life Sciences Spain I FCR continue to receive active support through the enlarged team, which brings AltamarCAM's institutional infrastructure and Asabys's deep sector expertise to bear on value creation for existing investments.